✦ LIBER ✦

Substituted Pyrazoles as Hepatoselective HMG-CoA Reductase Inhibitors: Discovery of (3 R ,5 R )-7-[2-(4-Fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2 H -pyrazol-3-yl]-3,5-dihydroxyheptanoic Acid (PF-3052334) as a Candidate for the Treatment of Hypercholesterolemia

✍ Scribed by Pfefferkorn, Jeffrey A.; Choi, Chulho; Larsen, Scott D.; Auerbach, Bruce; Hutchings, Richard; Park, William; Askew, Valerie; Dillon, Lisa; Hanselman, Jeffrey C.; Lin, Zhiwu; Lu, Gina H.; Robertson, Andrew; Sekerke, Catherine; Harris, Melissa S.; Pavlovsky, Alexander; Bainbridge, Graeme; Caspers, Nicole; Kowala, Mark; Tait, Bradley D.

Book ID: 121300804
Publisher: American Chemical Society
Year: 2008
Tongue: English
Weight: 670 KB
Volume: 51
Category: Article
ISSN: 0022-2623
DOI: 10.1021/jm070849r

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ChemInform Abstract: Discovery of a Fact

ChemInform Abstract: Discovery of a Factor Xa Inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic Acid 3-[(5-Chloro-pyridin-2-yl)-amide] 4-{[2-Fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide} as a Clinical Candidate.

✍ Wolfgang Haap; et al. et al. 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 23 KB 👁 2 views

## Abstract Compound (I) is found to be a potent, selective and orally bioavailable fXa inhibitor based on a pyrrolidine scaffold.